DEVELOPMENT AND LICENSE AGREEMENTS

BIOMUNEX develops its proprietary BiXAb® programs (TECHNOLOGY AND PRODUCTS – BI- AND MULTI-SPECIFIC ANTIBODY PIPELINE) up to clinical development (Phase I or II) and is open to discuss development partnership and out-licensing agreements with pharma and biotech companies regarding those programs, depending on potential synergy between partners.